Ambrx Biopharma Inc. (NYSE:AMAM – Get Rating)’s stock price traded up 3.6% on Friday . The stock traded as high as $2.02 and last traded at $1.99. 163,413 shares changed hands during mid-day trading, a decline of 83% from the average session volume of 964,432 shares. The stock had previously closed at $1.92.
Wall Street Analyst Weigh In
Separately, Robert W. Baird cut their price objective on shares of Ambrx Biopharma from $8.00 to $4.00 in a research report on Wednesday, October 19th.
Ambrx Biopharma Stock Performance
The company’s 50 day simple moving average is $1.53 and its 200 day simple moving average is $1.65.
Hedge Funds Weigh In On Ambrx Biopharma
Ambrx Biopharma Company Profile
Ambrx Biopharma Inc, a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer.
- Get a free copy of the StockNews.com research report on Ambrx Biopharma (AMAM)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for Ambrx Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ambrx Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.